Re-Designing of Existing Pharmaceuticals for Environmental Biodegradability: A Tiered Approach with β-Blocker Propranolol as an Example

Environmental Science and Technology

Volumn 49, Issue 19, 2015, Pages 11756-11763

  Rastogi, Tushar ^a   Leder, Christoph ^a   Kümmerer, Klaus ^a  

^a LEUPHANA UNIVERSITY OF LÜNEBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIODEGRADATION; EFFLUENT TREATMENT; EFFLUENTS; MOLECULES; PHOTOLYSIS; SUSTAINABLE DEVELOPMENT; WATER MANAGEMENT;

AEROBIC BIODEGRADABILITY; ENVIRONMENTAL PROBLEMS; LOW CONCENTRATIONS; MOLECULAR CHANGES; PROTECTION OF WATER RESOURCES; RATIONAL REDESIGN; RECENT RESEARCHES; SUSTAINABLE MANAGEMENT;

WATER RESOURCES;

DRUG DERIVATIVE; PROPRANOLOL; 4-HYDROXYPROPRANOLOL GLUCURONIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DRUG; WATER POLLUTANT;

AQUATIC ENVIRONMENT; BIODEGRADATION; DRUG; ENVIRONMENTAL DEGRADATION; ENVIRONMENTAL ISSUE; ENVIRONMENTAL PROTECTION; OXIC CONDITIONS; PHOTOLYSIS; SUSTAINABLE DEVELOPMENT; TOXICITY; WATER RESOURCE;

ANIMAL CELL; ARTICLE; BIODEGRADABILITY; COMPUTER MODEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; NONHUMAN; PHOTOLYSIS; AEROBIC METABOLISM; ANALOGS AND DERIVATIVES; ANALYSIS; BIOREMEDIATION; COMPUTER SIMULATION; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; REPRODUCIBILITY; TOXICITY TESTING; WATER POLLUTANT;

ADRENERGIC BETA-ANTAGONISTS; AEROBIOSIS; BIODEGRADATION, ENVIRONMENTAL; CHROMATOGRAPHY, LIQUID; COMPUTER SIMULATION; HUMANS; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS; PROPRANOLOL; REPRODUCIBILITY OF RESULTS; TOXICITY TESTS; WATER POLLUTANTS, CHEMICAL;

EID: 84943417506     PISSN: 0013936X     EISSN: 15205851     Source Type: Journal    
DOI: 10.1021/acs.est.5b03051     Document Type: Article

References (50)

1. Schwarzenbach, R.; Escher, B.; Fenner, K.; Hofstetter, T.; Johnson, C. A.; Urs von Gunten, W. B. The challenge of micropollutants in aquatic systems Science 2006, 313 (5790) 1072-1077 10.1126/science.1127291
2. Fenner, K.; Canonica, S.; Wackett, L. P.; Elsner, M. Evaluating Pesticide Degradation in the Environment: Blind Spots and Emerging Opportunities Science 2013, 341 (6147) 752-758 10.1126/science.1236281
3. Transformation products of emerging contaminants in the environment. Analysis, processes, occurrence, effects and risks; Lambropoulou, D. A.; Nollet, L. M. L., Eds.; John Wiley & Sons Inc: United Kingdom, 2014.
4. Trautwein, C.; Berset, J. D.; Wolschke, H.; Kümmerer, K. Occurrence of the antidiabetic drug Metformin and its ultimate transformation product Guanylurea in several compartments of the aquatic cycle Environ. Int. 2014, 70 (0) 203-212 10.1016/j.envint.2014.05.008
5. Richardson, S. D.; Ternes, T. A. Water Analysis: Emerging Contaminants and Current Issues Anal. Chem. 2014, 86 (6) 2813-2848 10.1021/ac500508t
6. Brodin, T.; Fick, J.; Jonsson, M.; Klaminder, J. Dilute Concentrations of a Psychiatric Drug Alter Behavior of Fish from Natural Populations Science 2013, 339 (6121) 814-815 10.1126/science.1226850
7. Loos, R.; Carvalho, R.; António, D. C.; Comero, S.; Locoro, G.; Tavazzi, S.; Paracchini, B.; Ghiani, M.; Lettieri, T.; Blaha, L.; Jarosova, B.; Voorspoels, S.; Servaes, K.; Haglund, P.; Fick, J.; Lindberg, R. H.; Schwesig, D.; Gawlik, B. M. EU-wide monitoring survey on emerging polar organic contaminants in wastewater treatment plant effluents Water Res. 2013, 47 (17) 6475-6487 10.1016/j.watres.2013.08.024
8. Mompelat, S.; Le Bot, B.; Thomas, O. Occurrence and fate of pharmaceutical products and by-products, from resource to drinking water: Pharmaceutical products in the environment: trends toward lowering presence and impact Environ. Int. 2009, 35 (5) 803-814 10.1016/j.envint.2008.10.008
9. Jones, O. A. H.; Green, P. G.; Voulvoulis, N.; Lester, J. N. Questioning the excessive use of advanced treatment to remove organic micropollutants from wastewater Environ. Sci. Technol. 2007, 41 (14) 5085-5089 10.1021/es0628248
10. Wenzel, H.; Larsen, H. F.; Clauson-Kaas, J.; Høibye, L.; Jacobsen, B. N. Weighing environmental advantages and disadvantages of advanced wastewater treatment of micro-pollutants using environmental life cycle assessment Water Sci. Technol. 2008, 57 (1) 27-32 10.2166/wst.2008.819
11. Kümmerer, K. Pharmaceuticals in the Environment. Sources, Fate, Effects and Risks, 3 rd ed.; Springer-Verlag: Berlin, Heidelberg, 2008.
12. Kümmerer, K. Sustainable from the very beginning: rational design of molecules by life cycle engineering as an important approach for green pharmacy and green chemistry Green Chem. 2007, 9 (8) 899-907 10.1039/b618298b
13. Kümmerer, K. The presence of pharmaceuticals in the environment due to human use-present knowledge and future challenges J. Environ. Manage. 2009, 90 (8) 2354-2366 10.1016/j.jenvman.2009.01.023
14. Anastas, P. T.; Warner, J. C. Green chemistry. Theory and Practice; Oxford University Press: New York, 1998.
15. Kümmerer, K. Drugs. In Handbook of Green Chemistry, Green Processes, Designing Safer Chemicals, Handbook of Green Chemistry 9; Anastas, P. T.; Boethling, R.; Votchkova, A., Eds.; Wiley-VCH: Weinheim, 2012; pp 215-280.
16. Black, J. W.; Crowther, A. F.; Shanks, R. G.; Smith, L. H.; Dornhorst, A. C. A new adrenergic: Beta-receptor antagonist Lancet 1964, 283 (7342) 1080-1081 10.1016/S0140-6736(64)91275-9
17. Lechat, P. Clinical pharmacology of beta-blockers in cardiology: trial results and clinical applications Hot Topics in Cardiology 2008, 10 (1) 7-44 10.4147/HTC-081000
18. WHOCC. WHOCC-ATC/DDD Index. http://www.whocc.no/atc-ddd-index/?code=C07AA05 (accessed September 9, 2014).
19. Arzneiverordnungs-Report 2013. Aktuelle Daten, Kosten, Trends und Kommentare; Schwabe, U.; Paffrath, D., Eds.; Springer-Verlag: Berlin, Heidelberg, 2013.
20. Bendz, D.; Paxéus, N. A.; Ginn, T. R.; Loge, F. J. Occurrence and fate of pharmaceutically active compounds in the environment, a case study: Höje River in Sweden J. Hazard. Mater. 2005, 122 (3) 195-204 10.1016/j.jhazmat.2005.03.012
21. Santos, L. H. M. L. M.; Araújo, A. N.; Fachini, A.; Pena, A.; Delerue-Matos, C.; Montenegro, M. C. B. S. M. Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic environment J. Hazard. Mater. 2010, 175 (1-3) 45-95 10.1016/j.jhazmat.2009.10.100
22. Gringauz, A. Introduction to Medicinal Chemistry. How Drugs Act and Why; Wiley-VCH: New York, 1997.
23. Gorre, F.; Vandekerckhove, H. Beta-blockers: focus on mechanism of action. Which beta-blocker, when and why? Acta Cardiol. 2010, 65 (5) 565-570
24. OECD. OECD Guidelines for the Testing of Chemicals. Ready Biodegradability 301D: Closed Bottle Test; OECD Pub., 1992.
25. OECD. OECD Guidelines for the Testing of Chemicals. Ready Biodegradability 301F: Manometric Respiratory Test; OECD Pub., 1992.
26. RCSB Protein Data Bank. RCSB Protein Data Bank-RCSB PDB. http://www.rcsb.org/pdb/home/home.do (accessed June 6, 2013).
27. Moukhametzianov, R.; Warne, T.; Edwards, P. C.; Serrano-Vega, M. J.; Leslie, A. G. W.; Tate, C. G.; Schertler, G. F. X. Two distinct conformations of helix 6 observed in antagonist-bound structures of a beta1-adrenergic receptor Proc. Natl. Acad. Sci. U. S. A. 2011, 108 (20) 8228-8232 10.1073/pnas.1100185108
28. Cherezov, V.; Rosenbaum, D. M.; Hanson, M. A.; Rasmussen, S. G. F.; Thian, F. S.; Kobilka, T. S.; Choi, H.-J.; Kuhn, P.; Weis, W. I.; Kobilka, B. K.; Stevens, R. C. High-Resolution Crystal Structure of an Engineered Human 2-Adrenergic G Protein Coupled Receptor Science 2007, 318 (5854) 1258-1265 10.1126/science.1150577
29. Jorgensen, W. L. Small-Molecule Drug Discovery Suite 2013-3: QikProp; Schrödinger: New York, 2013.
30. Saiakhov, R.; Chakravarti, S.; Sedykh, A. An improved workflow to perform in silico mutagenicity assessment of impurities as per ICH M7 guideline Toxicol. Lett. 2014, 229 (Supplement (0)) S164 10.1016/j.toxlet.2014.06.563
31. Leadscope. A new ICH M7 compliant expert alert system to predict the mutagenic potential of impurities. http://www.leadscope.com/white-papers/ICHM7-WhitePaper-0314.pdf (accessed April 9, 2015).
32. DiscoveRx. PathHunter® CHO-K1 ADRB1 β-ArrestinCell Line. http://www.discoverx.com/product-data-sheets-3-tab/93-0488c2 (accessed April 24, 2014).
33. DiscoveRx. PathHunter® β-Arrestin GPCR AssayPlatform. http://www.discoverx.com/technologies-platforms/enzyme-fragment-complementation-technology/pathhunter-efc-cell-based-assay-platform/protein-protein-interactions/gpcrs-b-arrestin (accessed April 24, 2014).
34. Liu, Q.-T.; Williams, H. E. Kinetics and Degradation Products for Direct Photolysis of β-Blockers in Water Environ. Sci. Technol. 2007, 41 (3) 803-810 10.1021/es0616130
35. Benner, J.; Ternes, T. A. Ozonation of Propranolol: Formation of Oxidation Products Environ. Sci. Technol. 2009, 43 (13) 5086-5093 10.1021/es900282c
36. Santiago-Morales, J.; Agüera, A.; Gómez, M. d. M.; Fernández-Alba, A. R.; Giménez, J.; Esplugas, S.; Rosal, R. Transformation products and reaction kinetics in simulated solar light photocatalytic degradation of propranolol using Ce-doped TiO2 Appl. Catal., B 2013, 129, 13-29 10.1016/j.apcatb.2012.09.023
37. Wilde, M. L.; Montipó, S.; Martins, A. F. Degradation of β-blockers in hospital wastewater by means of ozonation and Fe2+/ozonation Water Res. 2014, 48, 280-295 10.1016/j.watres.2013.09.039
38. Wilde, M. L.; Mahmoud, W. M. M.; Kümmerer, K.; Martins, A. F. Oxidation-coagulation of β-blockers by K2FeVIO4 in hospital wastewater: Assessment of degradation products and biodegradability Sci. Total Environ. 2013, 452-453 (0) 137-147 10.1016/j.scitotenv.2013.01.059
39. Howard, P. H. Biodegradation. In Handbook of Property Estimation Methods for Environmental Chemicals: Environmental and Health Sciences; Mackay, D.; Boethling, R. S., Eds.; Lewis Publishers: Boca Raton, 2000; pp 281-310.
40. Lyons, C.; Katz, S.; Bartha, R. Mechanisms and pathways of aniline elimination from aquatic environments Appl. Environ. Microbiol. 1984, 48 (3) 491-496
41. Nishino, S. F.; Spain, J. C. Cell density-dependent adaptation of Pseudomonas putida to biodegradation of p-nitrophenol Environ. Sci. Technol. 1993, 27 (3) 489-494 10.1021/es00040a006
42. Kümmerer, K.; Al-Ahmad, A.; Bertram, B.; Wieβler, M. Biodegradability of antineoplastic compounds in screening tests: influence of glucosidation and of stereochemistry Chemosphere 2000, 40 (7) 767-773 10.1016/S0045-6535(99)00451-8
43. Müller, T. A.; Kohler, H.-P. E. Chirality of pollutants-effects on metabolism and fate Appl. Microbiol. Biotechnol. 2004, 64 (3) 300-316 10.1007/s00253-003-1511-4
44. Sabela, M. I.; Gumede, N. J.; Escuder-Gilabert, L.; Martín-Biosca, Y.; Bisetty, K.; Medina-Hernández, M.-J.; Sagrado, S. Connecting simulated, bioanalytical, and molecular docking data on the stereoselective binding of (±)-catechin to human serum albumin Anal. Bioanal. Chem. 2012, 402 (5) 1899-1909 10.1007/s00216-011-5636-5
45. Li, W.; Liu, C.; Tan, G.; Zhang, X.; Zhu, Z.; Chai, Y. Molecular Modeling Study of Chiral Separation and Recognition Mechanism of β-Adrenergic Antagonists by Capillary Electrophoresis Int. J. Mol. Sci. 2012, 13 (12) 710-725 10.3390/ijms13010710
46. Boethling, R. S.; Sommer, E.; DiFiore, D. Designing Small Molecules for Biodegradability Chem. Rev. 2007, 107 (6) 2207-2227 10.1021/cr050952t
47. ICH. Assessment and cControl of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk M7. ICH M7 Genotoxic Impurities, Version 4, 2014.
48. Fitzgerald, J. D.; O'Donnell, S. R. Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol Br. J. Pharmacol. 1971, 43 (1) 222-235 10.1111/j.1476-5381.1971.tb07171.x
49. Walle, T.; Conradi, E. C.; Walle, U. K.; Fagan, T. C.; Gaffney, T. E. 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol Clin. Pharmacol. Ther. 1980, 27 (1) 22-31 10.1038/clpt.1980.4
50. Lee, H.-J.; Lee, E.; Yoon, S.-H.; Chang, H.-R.; Kim, K.; Kwon, J.-H. Enzymatic and microbial transformation assays for the evaluation of the environmental fate of diclofenac and its metabolites Chemosphere 2012, 87 (8) 969-974 10.1016/j.chemosphere.2012.02.018